CDMO Special Act 2026: Key Changes Bio SMEs Need to Know
The Special Act on the Promotion and Support of the Bio-pharmaceutical CDMO Industry, passed by the National Assembly in December 2025, is set to take effect in the second half of 2026. With the global CDMO market projected to reach approximately $270 billion by 2030, this legislation marks a pivotal regulatory shift that opens new market entry pathways for Korean bio SMEs.
Key Provisions of the CDMO Special Act
New Registration System for Export Manufacturing
Previously, contract biopharmaceutical manufacturers were subject to the same regulatory requirements as domestic product authorization. The Special Act introduces a dedicated registration system for export-oriented CDMO manufacturing, establishing a streamlined process for export-purpose contract production. This is expected to reduce the manufacturing license timeline from the current 12–18 months to approximately 6–9 months.
Codified GMP Compliance Standards for CDMO Facilities
The Act establishes CDMO-specific GMP compliance certification standards, distinct from conventional pharmaceutical manufacturing GMP. These standards address facility, equipment, and quality management criteria tailored to contract manufacturing operations. Notably, cleaning validation and cross-contamination prevention standards for multi-product changeover operations are explicitly defined, giving SMEs clear benchmarks for facility design.
Legal Framework for Raw Material Certification
For the first time, legal grounds for certification standards covering biopharmaceutical raw materials—including cell lines, culture media, and active pharmaceutical ingredients—have been established. Previously limited to guideline-level recommendations, these standards now carry statutory authority, significantly improving supply chain predictability.
Impact on Bio SMEs
Streamlined Facility Requirements for Export-Focused Sites
Export-dedicated CDMO facilities will benefit from rationalized facility standards compared to domestic manufacturing sites. A key provision exempts facilities from additional domestic requirements when they meet the GMP standards specified by the importer's destination country, reducing the initial capital investment burden.
Faster Export Customs Clearance
The Act introduces a priority customs processing system for CDMO-manufactured biopharmaceutical exports. Once the MFDS-Customs Service information linkage system is established, export clearance times are expected to decrease from the current average of 7–10 days to 3–5 days.
Leveraging the CDMO Regulatory Support Task Force
A dedicated CDMO Regulatory Support Task Force will be established under the Ministry of Food and Drug Safety (MFDS). SMEs can access one-stop support services including pre-authorization consultations, GMP certification guidance, and destination country regulatory intelligence.
Implementation Timeline and Preparation
Roadmap to 2026 Enforcement
Pre-Implementation Checklist
Bio SMEs should address the following critical items before the Act takes effect:
Market Entry Strategy for Bio SMEs
Step-by-Step GMP Compliance Roadmap
Leveraging Government R&D Programs
Bio CDMO has been designated a priority government R&D investment area for 2026. Strategic utilization of programs such as the MOTIE Bio Manufacturing Innovation Program, MSS Technology Development Grants, and KHIDI Bio-Health R&D initiatives can effectively offset facility investment and technology development costs.
KITIM Bio GMP Consulting Services
KITIM provides comprehensive consulting for bio SMEs preparing to enter the CDMO market, including GMP facility gap analysis, regulatory strategy development, and government R&D program linkage. From building a phased preparation roadmap aligned with the Special Act timeline to completing export manufacturing registration, our expert consultants deliver tailored support at every stage. Companies preparing for CDMO market entry are invited to request a consultation through the KITIM website or at contact@kitim.org.